C4 Therapeutics Inc
Daily Stock Prices Chart
This stock price chart for C4 Therapeutics Inc, symbol CCCC, Nasdaq Stock Exchange is updated
daily.
TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes.
[Remove symbol from "MyMenu"]
Weekly and Monthly charts are also available for C4 Therapeutics Inc.
Most Recent HeadlinesMNA: Dec 8th, 2024, 23:47Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 22:50Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 21:55Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 21:00Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 20:05Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 19:09Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 18:14Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 17:16Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 16:20Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 15:26Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 Degrader
|
